Prof Regina Scherließ

Prof. Dr. Regina Scherließ (*1979) is a professor for Pharmaceutics and Biopharmaceutics, managing director of the section Pharmacy and chair of the Department of Pharmaceutics at Kiel University, Germany.
As such she leads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics at Kiel University. She is a pharmacist and received her Dr. rer. nat. (doctor of natural sciences) in 2008 for a work on “Formulation of inhalation combination
products by co-precipitation”. In 2015 she finished her “habilitation” working on “Mucosal vaccination via the respiratory tract”. During her academic education she had research stays in Denmark, the US, New Zealand and Australia. She also received several young researcher awards including The Pat Burnell New Investigator Award 2010 of the Aerosol Society and is member of the DDL scientific committee (since 2015).
She also is member of the board of the research focus area KiNSIS (Kiel Nano Interface and Surface Sciences) at Kiel University. Her research interests include disperse systems and nanoparticles, stabilization of biomolecules and particle engineering in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. She is a co-founder of the Nasal Research Focus Group, a research consortium from academia and industry focusing on nasal drug delivery.

My research interests include disperse systems and nanoparticles, stabilisation of biomolecules and particle engineering in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery.
My work comprises formulation development and optimisation, functional characterisation as well as basic research exploring underlying principles in formulation and performance.
Recent projects work on novel non-spherical dry powder carriers, softpellets and drug nanocrystals for high dose application of powders to the lung, mucosal vaccination via the respiratory tract, nose-to-brain delivery, the in vitro assessment of nasal excipients, the exploration of surface energy in powders for inhalation and the development of nanoparticulate drug carrier systems.